1007377-55-0
1007377-55-0 structure
- Name: AKB-6899
- Chemical Name: AKB-6899
- CAS Number: 1007377-55-0
- Molecular Formula: C14H11FN2O4
- Molecular Weight: 290.25
- Catalog: Signaling Pathways Metabolic Enzyme/Protease HIF/HIF Prolyl-Hydroxylase
- Create Date: 2021-09-05 17:30:57
- Modify Date: 2024-01-28 05:35:10
-
AKB-6899, a prolyl hydroxylase domain 3 (PHD3) inhibitor, is a selective HIF-2α stabilizer. AKB-6899 also increases soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated macrophages, and has antitumor and antiangiogenic effects[1].
| Name | AKB-6899 |
|---|
| Description | AKB-6899, a prolyl hydroxylase domain 3 (PHD3) inhibitor, is a selective HIF-2α stabilizer. AKB-6899 also increases soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated macrophages, and has antitumor and antiangiogenic effects[1]. |
|---|---|
| Related Catalog | |
| In Vitro | AKB-6899 (10 μM; 24 hours) increases the leves of HIF-2α protein, with no corresponding increase in HIF-1α. AKB-6899 also increases soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated macrophages, with no effect on HIF-1α accumulation or VEGF production[1]. Western Blot Analysis[1] Cell Line: Murine bone marrow-derived macrophages Concentration: 10 μM Incubation Time: 24 hours Result: Observed an increase in HIF-2α protein in cells. |
| In Vivo | AKB-6899 (17.5 mg/kg; i.p.; 3 times per week; for 16 days) treatment significantly reduces tumor growth in a murine melanoma model[1]. Animal Model: 6-8-week-old C57BL/6 mice injected with B16F10 murine melanoma cells[1] Dosage: 17.5 mg/kg Administration: i.p.; 3 times per week; for 16 days Result: Significantly reduced tumor growth. |
| References |
| Molecular Formula | C14H11FN2O4 |
|---|---|
| Molecular Weight | 290.25 |